24th January 2001
Cancer Research Campaign Technology Appoints Cancer Research Ventures as Exclusive Agent
On 16th January 2001 Cancer Research Ventures (CRV) was appointed the exclusive agent of Cancer Research Campaign Technology (CRCT) for the purposes of conducting all new technology transfer business derived from research funded by The Cancer Research Campaign (The CRC).
The addition of the rich source of cancer technologies emanating from The CRC, expands CRV’s technology transfer and development business to include the majority of UK cancer funders as well as including many clients in Europe. CRV will also be strengthened by the addition of the staff and assets of CRCT to the CRV operations.
Enquiries
CRV
Dr. Keith Blundy, Acting Chief Operating Officer Tel: +44 (0) 20 7317 5205
Notes to the Editor
CRCT has been in existence since 1987 offering technology transfer services to researchers and universities funded by The Cancer Research Campaign. CRCT has undertaken a large number of major licensing deals and collaborations and more recently, it has spun off a number of successful biotech companies from The Cancer Research Campaign portfolio including Cyclacel, KuDOS Pharmaceuticals and Photo Therapeutics.
CRV was spun off from CRCT in 1998 after being awarded a Department of Trade and Industry BEP award. This company was developed in response to a large number of requests to offer oncology based technology transfer services outside of The Cancer Research Campaign. In the two years since then, CRV has developed business relationships with a number of UK funding organisations and European research institutes and successfully commercialised several technologies from their research via collaboration/license deals and two start-up companies, Crusade Labs and Qugen Therapeutics.
|
